Omeros Corp OMER

$18.61 +0.14 (0.76%)

Valuation

Market cap
1,337,006,000
Revenue TTM
$0
Net income TTM
$-3,350,000
PE ratio
6.97
Forward PE
—
Profit margin
0.00%
Debt to equity
-1.89

Trading

Volume
956,300
Avg volume
1,890,678
Day's range
$18.22 – $18.76
Shares out
72,388,000
Stochastic %K
13%
Beta
2.57
Analysts
Strong Sell
Price target
$36.67

Price

Company profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COV...

Show more

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Industry
Biotechnology
Sector
Healthcare
Phone
206 676 5000
Website
https://www.omeros.com
Address
The Omeros Building, 201 Elliott Avenue West, Seattle, United States

Latest news

Stocktwits

Merlintrader Oct 3, 6:37 PM
Omeros ($OMER) Stock Hub: NTAP Is Live, Europe Is Pending — Can YARTEMLEA Carry the Balance Sheet? The operating thesis remains YARTEMLEA demand, the October 1 NTAP activation, liquidity after the July note repurchases and the unresolved European review. https://www.merlintrader.com/omeros-corporation-stock-hub/
0 replies
KryptonResearch14 Oct 3, 5:59 AM
$OMER Omeros is targeting enrollment by year-end 2026 in the NIDA-funded Phase 1b inpatient trial of OMS527 for cocaine use disorder. The structure is the cheap optionality. NIDA fully funds the program. Omeros is developing its PDE7 inhibitor at the agency's request, and the preclinical interaction studies, designed with NIDA toxicologists, came back with no drug-interaction or safety issues. The gate was the FDA. It asked for additional nonclinical information before the inpatient trial, so Omeros is running that nonclinical study now to unblock enrollment. The mechanism: PDE7 inhibition modulates signaling in the brain's dopamine axis without depressing the reward system, which is the main drawback of marketed anti-addiction agents. There is no approved treatment for cocaine use disorder.
1 replies
kreftslag Oct 3, 5:49 AM
$OMER OMS527 update Omeros targets start of the NIDA-funded Phase 1b inpatient trial in cocaine users this quarter (by year-end 2026). First data expected mid-to-late 2027. Fully funded by NIDA → zero cash burn for Omeros. Clean preclinical interaction studies + solid Phase 1 in healthy volunteers. Realistic take: interesting low-risk side bet. The fact that NIDA is fully sponsoring this (one of the few programs they back this heavily) means they clearly see real potential in the PDE7 mechanism. Addiction trials are tough, but the unmet need is massive and the data so far look promising. Not a near-term driver vs Yartemlea, but a nice free option in the pipeline.
0 replies
Phase3 Oct 2, 8:01 PM
$OMER Nice close, for a Friday. 👍
1 replies
TheNewAxe Oct 2, 7:59 PM
$OMER Added
0 replies
izacmann Oct 2, 7:59 PM
$OMER run into the close!
0 replies
mendergill Oct 2, 6:52 PM
$OMER Day traders/shorties having some fun poking a sleeping giant with the cute daily swings... it's all fun until the monster wakes up exploding! Then they struggle to keep up with it!
1 replies
resq1 Oct 2, 4:42 PM
$OMER this pattern repeated itself, dropping systematically for 2-3 weeks without any resistance then pop, up 30%
0 replies